BOSTON and MONTREAL, Nov. 29,
2023 /CNW/ - enGene Holdings Inc. ("enGene,")
(NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines
company whose lead program is in a pivotal study for
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today
announced the appointment of Ryan
Daws as Chief Financial Officer and Head of Business
Development.
"I am delighted to welcome Ryan to enGene at a critical time in
our growth, as we move forward as a public company and work to
advance our ongoing pivotal-stage EG-70 clinical study in
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)," said
Jason D. Hanson, Chief Executive
Officer of enGene. "Ryan's significant experience across multiple
areas of financial, business development and operational management
in the pharmaceutical industry, as well as healthcare investment
banking, complements our leadership team. We look forward to
working with Ryan to continue to serve our shareholders,
clinicians, and ultimately patients, in pursuit of our longstanding
goal of mainstreaming gene therapy and bringing our genetic
medicines to community clinics across the globe."
Mr. Daws joins enGene with nearly 25 years of life
sciences-focused operational and deal-making experience. Prior to
joining enGene, Mr. Daws was Chief Financial Officer and Head of
Business Development at Obsidian Therapeutics, Inc. In that role,
he was responsible for finance, business development, information
technology, investor relations and facilities functions. Prior to
joining Obsidian Therapeutics, Mr. Daws was Managing Director with
the Healthcare Investment Banking Group at Robert W. Baird &
Co., Inc. where he was responsible for IPOs, follow-on offerings,
private placements and mergers and acquisition transactions in the
life sciences sector. Mr. Daws also previously served as Chief
Financial Officer and Head of Business Development at Concert
Pharmaceuticals, Inc. Prior to Concert Pharmaceuticals, Mr. Daws
spent nearly 15 years originating and executing equity and mergers
and acquisitions transactions in the life sciences sector, first at
Cowen and Company, LLC and then Stifel, Nicolaus & Co, Inc. Mr.
Daws earned his International Master of Business Administration and
Bachelor of Science in Business Administration from the
University of South Carolina.
Mr. Daws commented, "This is an exciting time to join
enGene, with our pivotal clinical study in BCG-unresponsive NMIBC
actively enrolling patients and progressing towards our anticipated
interim data read-out in mid-2024. We have a compelling opportunity
to advance a new era of genetic medicines to reach larger patient
populations, and I look forward to working alongside the team in
furtherance of our mission."
About enGene
enGene is a clinical-stage biotechnology company mainstreaming
genetic medicines through the delivery of therapeutics to mucosal
tissues and other organs, with the goal of creating new ways to
address diseases with high clinical needs. enGene's lead program is
EG-70 for patients with non-muscle invasive bladder cancer (NMIBC)
with carcinoma in situ (Cis) who are unresponsive or naïve to
treatment with Bacillus Calmette-Guérin (BCG) - a disease with a
high clinical burden. EG-70 is being evaluated in an ongoing Phase
2 pivotal study. EG-70 was developed using enGene's proprietary
Dually Derivatized Oligochitosan (DDX) platform, which enables
penetration of mucosal tissues and delivery of a wide range of
sizes and types of cargo, including DNA and various forms of RNA.
enGene became a publicly traded company effective November 1, 2023, upon the completion of a
business combination with Forbion European Acquisition Corporation,
a special purpose acquisition company. For more information, visit
enGene.com.
Forward-Looking
Statements
Some of the statements contained in this press release may
constitute forward-looking statements within the meaning of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995, and "forward-looking information" within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). enGene's forward-looking statements include, but are
not limited to, statements regarding enGene's expectations, hopes,
beliefs, intentions, goals, strategies, forecasts and projections.
The words "anticipate", "appear", "approximate", "believe",
"continue", "could", "estimate", "expect", "foresee", "intend",
"may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would", and similar expressions may
identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking.
Forward-looking statements may include, for example, statements
about: enGene's goal of mainstreaming gene therapy and bringing
genetic medicines to community clinics across the globe and the
expected timeline for the interim Phase 2 results from the EG-70
program.
Many factors, risks, uncertainties and assumptions could cause
the Company's actual results, performance or achievements to differ
materially from those expressed or implied by the forward-looking
statements, including, without limitation, the Company's ability to
recruit and retain qualified scientific and management personnel,
establish clinical trial sites and patient registration for
clinical trials and acquire technologies complimentary to, or
necessary for, its programs; the Company's ability to address
diseases with high clinical needs; the Company's ability to retain
commercial rights to EG-70 in the United
States and commercialize EG-70 independently, while
selectively partnering outside of the
United States; the Company's plans and ability to secure
regulatory approval, to execute product development, manufacturing
process development, preclinical and clinical development efforts
successfully and on anticipated timelines; enGene's ability to
design mainstream gene therapy and bring genetic medicines to
community clinics across the globe; and other risks and
uncertainties detailed in filings with Canadian securities
regulators on SEDAR+ and with the U.S. Securities and Exchange
Commission ("SEC") on EDGAR, including those described in the "Risk
Factors" section of the Registration Statement on Form S-1 filed by
the Company with the SEC on November 21,
2023 (copies of which may be obtained at
sedarplus.ca or www.sec.gov).
You should not place undue reliance on any forward-looking
statements, which speak only as of the date on which they are made.
enGene anticipates that subsequent events and developments will
cause enGene's assessments to change. While enGene may elect to
update these forward-looking statements at some point in the
future, enGene specifically disclaims any obligation to do so,
unless required by applicable law. Nothing in this press release
should be regarded as a representation by any person that the
forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking
statements will be achieved.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/engene-appoints-ryan-daws-as-chief-financial-officer-301999836.html
SOURCE enGene